1Postgraduate, Department of General Surgery, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India. Email: pradeepkumar.m19@gmail.com
2Assistant Professor, Department of General Surgery, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India. Email: valaram.941@gmail.com
3Assistant Professor, Department of General Surgery, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India. Email: manibal27@gmail.com
4Senior Resident, Department of Pharmacology, Northern Eastern Indhira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS), Mawdiangdiang, Shillong, Meghalaya-793018. Email: raj07b@gmail.com
5Postgraduate, Department of General Surgery, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India. Email: dr.lalith2322@gmail.com
*Corresponding Author: Dr. Ramprasath E, Assistant Professor, Department of General Surgery, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India. Email: valaram.941@gmail.com
Received: 20th Oct, 2025; Revised: 22th Dec, 2025; Accepted: 22th Jan, 2026; Available Online: 17th Feb, 2026
Background: Neoadjuvant chemotherapy is an integral component in the management of locally advanced breast cancer, facilitating tumor downstaging and improving surgical outcomes. Anthracycline-based multidrug regimens are commonly used; however, single-agent taxane therapy may be a suitable alternative in selected patients. This study compared the effectiveness and tolerability of an anthracycline-based multidrug regimen versus single-agent Paclitaxel as NACT in LABC.
Methods: This prospective comparative study included 20 patients with LABC, divided into two groups: AC regimen (n = 10) and single-agent Paclitaxel (n = 10). Baseline clinicopathological characteristics, treatment response, adverse events (grade ≥2), surgical outcomes, and postoperative axillary nodal status were assessed. Clinical and pathological responses were evaluated following completion of NACT.
Results: The overall clinical response rate was 80% in both groups. Pathological complete response was achieved in 30% of patients in the AC group and 20% in the Paclitaxel group. Breast conservation surgery was performed in 60% of patients receiving AC and 50% receiving Paclitaxel. Hematologic toxicities, including neutropenia and anemia, were more frequent in the AC group, whereas non-hematologic toxicities such as peripheral neuropathy and myalgia/arthralgia were significantly higher in the Paclitaxel group.
Conclusion: Both AC and single-agent Paclitaxel demonstrated comparable efficacy as neoadjuvant chemotherapy in LABC. While AC showed a slightly higher pathological complete response, Paclitaxel offered similar clinical and surgical outcomes with reduced hematologic toxicity. Treatment selection should be individualized based on patient tolerance and clinical profile.
Keywords: Locally advanced breast cancer; Neoadjuvant chemotherapy; Anthracycline-based regimen; Paclitaxel; Pathological complete response
How to cite this article: Kumar PM, Ramprasath E, Manibalan S, Kumar R, Kumar DL, Effectiveness Of Multidrug Regimen (Ac) Vs Single Agent (Paclitaxel) Neo Adjuvant Chemotherapy In Labc- A Prospective Study...Int J Drug Deliv Technol. 2026; 16(2): 322-326; DOI: 10.25258/ijddt.16.2.35
Source of support: Nil.
Conflict of interest: None